BridgeMD
New treatment option for Insulin Resistance
Official title Metabolic Heterogeneity Underlying Hypertriglyceridemia: Hepatic Triglyceride Biosynthesis in Humans With Different Insulin Resistance Phenotypes
ClinicalTrials.gov ID: NCT05743868
What this study is testing
- What it's testing
- The focus of this cross-sectional study is to determine the effects of tissue-specific (adipose tissue or muscle) vs global (combined) insulin resistance (IR) on hepatic triglyceride biosynthesis in humans, and to determine differential effects of an acute exercise intervention on hepatic triglyceride biosynthesis in these groups.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Ability to give informed consent
- Overweight, defined as BMI 25-30 kg/m2
- Modest hypertriglyceridemia, defined as fasting plasma triglycerides 1.5-3.0mM
- High risk of insulin resistance, defined as fasting plasma insulin \>64pM
- Stable weight for at least 3mo prior to participation
You likely can't join if
- Active or chronic liver disease, kidney disease, congestive heart failure, unstable angina, history of acute cardiovascular events within 6mo of...
- Use of insulin, thiazolidinediones, SGLT2 inhibitors, or sulfonylureas;
- Use of fibrates, omega 3 (fish oil), niacin, or PCSK9 antagonists;
- Use of systemic glucocorticoids within 60d prior to participation;
- Hematocrit \<35%;
- Pregnancy of breastfeeding;
See the full eligibility criteria
- Ability to give informed consent
- Overweight, defined as BMI 25-30 kg/m2
- Modest hypertriglyceridemia, defined as fasting plasma triglycerides 1.5-3.0mM
- High risk of insulin resistance, defined as fasting plasma insulin \>64pM
- Stable weight for at least 3mo prior to participation
- Active or chronic liver disease, kidney disease, congestive heart failure, unstable angina, history of acute cardiovascular events within 6mo of screening, history of seizures or syncope, or an active infection...
- Use of insulin, thiazolidinediones, SGLT2 inhibitors, or sulfonylureas;
- Use of fibrates, omega 3 (fish oil), niacin, or PCSK9 antagonists;
- Use of systemic glucocorticoids within 60d prior to participation;
- Hematocrit \<35%;
- Pregnancy of breastfeeding;
- Active tobacco use, excessive alcohol intake (\>14U/wk), or history of drug abuse.
The study team makes the final eligibility decision.
Where it's taking place
- Amsterdam, Netherlands
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Amsterdam, Netherlands. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.